Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.73+1.03 (+6.17%)
Close on Nov 18, 2026Market cap $1.75BP/E –Yield –
Ultragenyx Pharmaceutical total assets
Total assets on the balance sheet at the end of each period.
Ultragenyx Pharmaceutical's total assets was $1.26B at Jun 30, 2026. For fiscal 2025 it was $1.53B, up 1.9% from the year before. Over ten years it grew 10.6% a year on average. The highest annual figure on record is $1.76B in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.53B | +1.9% |
| FY2024 | Dec 31, 2024 | $1.50B | +0.8% |
| FY2023 | Dec 31, 2023 | $1.49B | -3.5% |
| FY2022 | Dec 31, 2022 | $1.55B | +1.5% |
| FY2021 | Dec 31, 2021 | $1.52B | -13.5% |
| FY2020 | Dec 31, 2020 | $1.76B | +55.0% |
| FY2019 | Dec 31, 2019 | $1.14B | +57.8% |
| FY2018 | Dec 31, 2018 | $719.56M | +46.6% |
| FY2017 | Dec 31, 2017 | $490.75M | -9.2% |
| FY2016 | Dec 31, 2016 | $540.63M | -3.4% |
| FY2015 | Dec 31, 2015 | $559.57M | +182.7% |
| FY2014 | Dec 31, 2014 | $197.97M | +231.9% |
| FY2013 | Dec 31, 2013 | $59.65M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.26B | -3.2% |
| Q1 FY2026 | Mar 31, 2026 | $1.30B | -1.2% |
| Q4 FY2025 | Dec 31, 2025 | $1.53B | +1.9% |
| Q3 FY2025 | Sep 30, 2025 | $1.19B | -22.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.31B | -19.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.31B | +0.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.50B | +0.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.54B | +24.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.62B | +23.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.31B | -5.5% |
| Q4 FY2023 | Dec 31, 2023 | $1.49B | -3.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.24B | -23.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.31B | -0.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.38B | -0.0% |
| Q4 FY2022 | Dec 31, 2022 | $1.55B | +1.5% |
| Q3 FY2022 | Sep 30, 2022 | $1.62B | +9.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.32B | -12.7% |
| Q1 FY2022 | Mar 31, 2022 | $1.38B | -13.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.52B | -13.5% |
| Q3 FY2021 | Sep 30, 2021 | $1.48B | +17.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.51B | +15.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.60B | +29.6% |
| Q4 FY2020 | Dec 31, 2020 | $1.76B | +55.0% |
| Q3 FY2020 | Sep 30, 2020 | $1.27B | +44.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.31B | +37.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.23B | +22.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.14B | +57.8% |
| Q3 FY2019 | Sep 30, 2019 | $879.94M | +15.0% |
| Q2 FY2019 | Jun 30, 2019 | $958.93M | +19.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.01B | +23.3% |
| Q4 FY2018 | Dec 31, 2018 | $719.56M | +46.6% |
| Q3 FY2018 | Sep 30, 2018 | $765.15M | +75.9% |
| Q2 FY2018 | Jun 30, 2018 | $806.02M | +62.0% |
| Q1 FY2018 | Mar 31, 2018 | $817.35M | +49.7% |
| Q4 FY2017 | Dec 31, 2017 | $490.75M | -9.2% |
| Q3 FY2017 | Sep 30, 2017 | $435.05M | -15.6% |
| Q2 FY2017 | Jun 30, 2017 | $497.54M | – |
| Q1 FY2017 | Mar 31, 2017 | $545.82M | – |
| Q4 FY2016 | Dec 31, 2016 | $540.63M | – |
| Q3 FY2016 | Sep 30, 2016 | $515.17M | – |
See a number that looks wrong?